Treatment-Resistant Depression Treatment Market Size, Share & Growth Analysis, [2030] | With CAGR of 11.0%
11 déc. 2023 08h48 HE
|
Fortune Business Insights
Pune, India, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The treatment-resistant depression treatment market size is projected to grow from USD 1.95 billion in 2023 to USD 4.06 billion by 2030, exhibiting a...
Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus, Novartis, Relmada, Beckley Psytech, COMPASS, Axsome, Celon Pharma
19 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus,...
With 9.0% CAGR, Treatment-Resistant Depression Treatment Market Size Worth USD 2.83 Billion by 2029
04 nov. 2022 06h39 HE
|
Fortune Business Insights
Pune, India, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The global treatment-resistant depression treatment market size was valued at USD 1.52 billion in 2021. The market is projected to grow from USD 1.55...
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
23 mai 2022 07h00 HE
|
COMPASS Pathways
Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a...
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
03 mai 2022 07h00 HE
|
COMPASS Pathways
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022 COMPASS...
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
19 janv. 2022 07h00 HE
|
COMPASS Pathways
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
04 janv. 2022 07h00 HE
|
COMPASS Pathways
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January...
COMPASS Pathways announces changes in Executive Team
16 déc. 2021 07h40 HE
|
COMPASS Pathways
Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role London, UK – 16 December...
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
13 déc. 2021 07h00 HE
|
COMPASS Pathways
Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trialAll patients tolerated COMP360...
Michael Falvey joins COMPASS Pathways as Chief Financial Officer
03 déc. 2021 07h00 HE
|
COMPASS Pathways
London, UK - 3 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...